OXFORD, England, October 4, 2011 /PRNewswire/ --
PharmaVentures today announced the appointment of Andy Smith as Head of Corporate Finance to significantly enhance Pharmaventures' advisory capabilities and offerings to the global healthcare and investment communities.
Fintan Walton, PhD, PharmaVentures' Chief Executive Office says "We are delighted to welcome Andy to PharmaVentures. He brings a wealth of investment management experience and has also worked extensively across R&D and marketing in the healthcare sector. At PharmaVentures we are increasingly providing more investment bank style services to help our clients with their dealmaking and Andy's addition to PharmaVentures will therefore be of great benefit."
Andy has a PhD in molecular Biology and an MBA in International Marketing. He has previously worked with Investment Managers 3i, Schroders Plc and AXA Framlington. In 2007 he was awarded the techmark Technology Fund Manager of the year. Since 2011 Andy has written a regular weekly column; Stockwatch, in Scrip and has lectured on healthcare valuations and modeling at the University of Cambridge for the last six years.
PharmaVentures Limited (http://www.pharmaventures.com) is a leading international corporate advisory firm supporting its clients' growth ambitions in the health care industry. It has considerable experience and expertise in the field of tangible and intangible transactions, providing advice at both a strategic level, as well as acting as advisor and broker at an implementation level. Its transactional experience includes licensing, joint ventures, mergers, acquisitions and divestments. Its clients are worldwide, including Europe, the USA and AsiaPacific. Clients range from start-ups to global pharmaceutical corporations, diversified industrial corporations, investment houses and government bodies. Its subsidiary PharmaTelevisio
Copyright©2010 PR Newswire.
All rights reserved